Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
LaggingWe are a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. We currently market two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor that was discovered and developed by Ardelyx. NHE3 is an antiporter expressed on the apical surface of the small and large intestines.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Business segments
Jun 2026 · $123.6MThe company’s own SEC segment disclosure.
- Product IBSRELA$86.2M70%
- Product XPHOZAH$31.9M26%
- Product And Service Other$2.7M2%
- Product Supply$2.0M2%
- Non Cash Royalty Related To Sale Of Future Royalties$676.0K1%
- License$96.0K0%
Ardelyx, Inc. (ARDX) reported revenue of $94M in Q1 2026 (quarter ended Mar 31, 2026), up 27% from the same quarter a year earlier. That came with a gross margin of 95% and net loss of $38M. For the full year FY2025, revenue was $407M (+22% year on year) and net income −$62M. Its largest product in Jun 2026 was Product IBSRELA at $86M, 70% of the disclosed total, well ahead of Product XPHOZAH at 26%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.